Vandebroek Sophie V. 4

What Happened

• Sophie V. Vandebroek, a director of IDEXX Laboratories (IDXX), received equity awards on 2026-05-12 consisting of 525 stock option awards and 234 restricted stock units (RSUs), reported as derivative acquisitions (code A). Both awards are listed at $0.00 in the filing (grant/award), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (timely within standard 2-business-day window).
• Awards: 525 options (F1) + 234 RSUs (F2) = 759 total derivative awards; reported price per share: $0.00 (grant).
• Vesting: Both awards vest in one installment on the one-year anniversary of the grant or on the date of the 2027 annual meeting of shareholders, whichever is earlier (see footnotes F1 and F2).
• Shares owned after transaction: Not specified in the supplied excerpt of the filing.
• Transaction type: Award/grant (compensation), not a purchase, sale, or exercise.

Context

• The 525-item award are options (right to buy shares if vested/exercised); the 234 RSUs represent a contingent right to receive shares at vesting. Neither increases her common shares outstanding immediately — RSUs convert to shares only at vesting and options require exercise.
• Such equity awards are commonly part of director compensation and are routine; they do not by themselves indicate buying or selling sentiment.